Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)
Sweden
· Delayed Price · Currency is SEK 49.50
+1.30 (2.70%)
Apr 23, 2025, 5:19 PM CET
STO:IBT.B Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 223.39 | 329.06 | 335.84 | 386.75 | 423.44 | Upgrade
|
| Cash & Short-Term Investments | 223.39 | 329.06 | 335.84 | 386.75 | 423.44 | Upgrade
|
| Cash Growth | -32.11% | -2.02% | -13.16% | -8.66% | -14.49% | Upgrade
|
| Other Receivables | 4.77 | 6.74 | 1.78 | 1.2 | 1.96 | Upgrade
|
| Receivables | 4.77 | 6.74 | 1.78 | 1.2 | 1.96 | Upgrade
|
| Prepaid Expenses | 2.46 | 5.76 | 1.41 | 9.14 | 12.73 | Upgrade
|
| Other Current Assets | 0 | - | 0 | - | - | Upgrade
|
| Total Current Assets | 230.61 | 341.56 | 339.03 | 397.09 | 438.12 | Upgrade
|
| Long-Term Investments | 0.07 | 0.07 | 0.07 | 0.05 | 0.05 | Upgrade
|
| Long-Term Deferred Charges | 8.89 | 9.7 | 10.52 | 11.33 | 12.15 | Upgrade
|
| Other Long-Term Assets | - | -0 | - | - | - | Upgrade
|
| Total Assets | 239.57 | 351.33 | 349.62 | 408.48 | 450.32 | Upgrade
|
| Accounts Payable | 46.99 | 30.07 | 8.75 | 4.8 | 1.23 | Upgrade
|
| Accrued Expenses | 21.89 | 15.33 | 8.67 | 7.65 | 6.87 | Upgrade
|
| Other Current Liabilities | 0.42 | 0.78 | 0.5 | 0.78 | 2.07 | Upgrade
|
| Total Current Liabilities | 69.3 | 46.18 | 17.91 | 13.22 | 10.16 | Upgrade
|
| Other Long-Term Liabilities | - | - | 0 | - | - | Upgrade
|
| Total Liabilities | 69.3 | 46.18 | 17.91 | 13.22 | 10.16 | Upgrade
|
| Common Stock | 3.67 | 3.67 | 3.06 | 3.06 | 3.06 | Upgrade
|
| Additional Paid-In Capital | 768.84 | 766.83 | 670.93 | 669.02 | 668.93 | Upgrade
|
| Retained Earnings | -602.25 | -465.35 | -342.28 | -276.83 | -231.84 | Upgrade
|
| Comprehensive Income & Other | - | 0 | -0 | - | - | Upgrade
|
| Shareholders' Equity | 170.26 | 305.15 | 331.71 | 395.25 | 440.15 | Upgrade
|
| Total Liabilities & Equity | 239.57 | 351.33 | 349.62 | 408.48 | 450.32 | Upgrade
|
| Net Cash (Debt) | 223.39 | 329.06 | 335.84 | 386.75 | 423.44 | Upgrade
|
| Net Cash Growth | -32.11% | -2.02% | -13.16% | -8.66% | -14.49% | Upgrade
|
| Net Cash Per Share | 16.58 | 26.61 | 29.92 | 34.45 | 37.72 | Upgrade
|
| Filing Date Shares Outstanding | 13.47 | 13.47 | 11.23 | 11.23 | 11.23 | Upgrade
|
| Total Common Shares Outstanding | 13.47 | 13.47 | 11.23 | 11.23 | 11.23 | Upgrade
|
| Working Capital | 161.31 | 295.38 | 321.12 | 383.87 | 427.95 | Upgrade
|
| Book Value Per Share | 12.64 | 22.65 | 29.55 | 35.21 | 39.21 | Upgrade
|
| Tangible Book Value | 170.26 | 305.15 | 331.71 | 395.25 | 440.15 | Upgrade
|
| Tangible Book Value Per Share | 12.64 | 22.65 | 29.55 | 35.21 | 39.21 | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.